The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UK.
Dermatol Ther (Heidelb). 2012 Dec;2(1):7. doi: 10.1007/s13555-012-0007-5. Epub 2012 May 25.
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, with multisystem involvement, including cutaneous manifestations of hyperpigmentation and neurofibromas. Multiple cutaneous lesions are often disfiguring and lead to emotional distress and social isolation. Treatment of NF1 is predominantly surgical but alternative treatments should be considered for patients with large numbers of lesions as cold steel excision of multiple lesions can be cumbersome and may not be practical. The authors report a series of patients with multiple neurofibromas successfully treated using a CO(2) laser.
Data on CO(2) laser treatments, follow-up, and recurrence following treatment was collected retrospectively. A post-treatment telephone survey was carried out to assess patient satisfaction using a standardized set of questions and a scoring tool.
Five of seven patients who underwent CO(2) laser treatment of their multiple neurofibromas responded to the post-treatment survey. All five patients (age range 36-56 years, mean age 45.2 years, three men:two women) had multiple variable-sized neurofibromas. The mean number of lesions per patient was 114 (range 20-200 lesions). The mean number of treatment sessions was 2.2 (range 1-4 sessions) and mean follow-up was 14.4 months (range 6-24 months). Three patients (60%) reported no recurrence up to 2 years post-laser treatment. Two patients (40%) had recurrences of a few lesions (≤10% of treated lesions per patient). The mean patient satisfaction score was 9.2 out of 10 (range 8-10). All patients mentioned that they would recommend CO(2) laser treatment to others with multiple neurofibromas. Hypopigmentation or depigmentation at treatment sites were the only reported adverse effects.
Based on current results, the authors feel that CO(2) laser treatment achieves a high level of patient satisfaction with a low recurrence of treated lesions.
神经纤维瘤病 1 型(NF1)是一种常染色体显性遗传疾病,多系统受累,包括皮肤色素沉着和神经纤维瘤的表现。多发性皮肤病变常常会造成毁容,并导致情绪困扰和社交孤立。NF1 的治疗主要是手术,但对于有大量病变的患者,应考虑替代治疗,因为冷钢切除多个病变可能很麻烦,并且可能不切实际。作者报告了一系列使用 CO2 激光成功治疗多发性神经纤维瘤的患者。
回顾性收集 CO2 激光治疗、随访和治疗后复发的数据。通过电话进行治疗后调查,使用一套标准化问题和评分工具评估患者满意度。
7 名接受 CO2 激光治疗多发性神经纤维瘤的患者中有 5 名对治疗后调查做出了回应。所有 5 名患者(年龄 36-56 岁,平均年龄 45.2 岁,男性 3 名,女性 2 名)均有多发性大小不一的神经纤维瘤。每位患者的平均病变数为 114 个(病变范围 20-200 个)。平均治疗次数为 2.2 次(范围 1-4 次),平均随访时间为 14.4 个月(范围 6-24 个月)。3 名患者(60%)在激光治疗后 2 年内无复发报告。2 名患者(40%)有少数病变(每个患者治疗病变的 10%以下)复发。患者满意度平均评分为 10 分中的 9.2 分(范围 8-10 分)。所有患者均表示会向其他多发性神经纤维瘤患者推荐 CO2 激光治疗。治疗部位出现色素减退或脱失是唯一报告的不良反应。
根据目前的结果,作者认为 CO2 激光治疗可获得较高的患者满意度,且治疗病变的复发率较低。